Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For Novavax, Building Trust Was Key To Improving Diversity

Company Took Lead In Native American Vaccine Study Enrollment

Executive Summary

Novavax’s Lisa Dunkle talked to Scrip about the time and effort that went into building trust among Native American communities to encourage participation in its COVID-19 vaccine study.

You may also be interested in...



Trials In Focus: How COVID-19 Studies Set New Standards For Collaboration, Diversity

JAMA reports on the COVID-19 Prevention Network’s efforts. Also, Inhibikase said the US FDA lifted a hold on its drug for Parkinson’s disease, while Astellas Pharma said the agency lifted a clinical hold on its gene therapy for Pompe disease. And Trefoil, Theriva Biologics and Nektar initiated new trials.

Pivotal Trials For EU Approval Still Underrepresent Minorities, Study Finds

Data on minority groups were frequently underreported, and in many cases numbers have not improved with time, according to the study by Tufts CSDD.

Pivotal Trials For EU Approval Still Underrepresent Minorities, Study Finds

The study, by Tufts CSDD, also found that data on minority groups were frequently underreported, and in many cases numbers have not improved with time.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel